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Abstract Remote monitoring of cardiac implanted electronic
devices (CIED: pacemaker, cardiac resynchronisation therapy
device and implantable cardioverter defibrillator) has been
developed for technical control and follow-up using transtele-
phonic data transmission. In addition, automatic or patient-
triggered alerts are sent to the cardiologist or allied professional
who can respond if necessary with various interventions. The
advantage of remote monitoring appears obvious in impending
CIED failures and suspected symptoms but is less likely in
routine follow-up of CIED. For this follow-up the indications,
quality of care, cost-effectiveneness and patient satisfaction
have to be determined before remote CIED monitoring can
be applied in daily practice. Nevertheless remote CIED mon-
itoring is expanding rapidly in the Netherlands without
professional agreements about methodology, responsibilities
of all the parties involved and that of the device patient, and
reimbursement. The purpose of this consensus document on
remote CIED monitoring and follow-up is to lay the base for a
nationwide, uniform implementation in the Netherlands. This
report describes the technical communication, current indica-
tions, benefits and limitations of remote CIED monitoring and
follow-up, the role of the patient and device manufacturer, and
costs and reimbursement. The view of cardiology experts and
of other disciplines in conjunction with literature was incorpo-
rated in a preliminary series of recommendations. In addition,
an overview of the questions related to remote CIED monitor-
ing that need to be answered is given. This consensus docu-
ment can be used for future guidelines for the Dutch profession.
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Abbreviations
AF Atrial fibrillation
CIED Cardiovascular implantable electronic device
CRT Cardiac resynchronization therapy
DDDR Mode of atrial-ventricular cardiac pacing
DICOM Digital imaging and communications in medicine
EPR Electronic patient record
EHR Electronic health record
ERI Elective replacement indicator
GPRS General packet radio service
GSM Global system for mobile communications
GUI Graphical user interface
HL7 Health level seven, international healthcare standard
https Secure internet connection
ICD Implantable cardioverter defibrillator
IDCO Implantable device–cardiac–observation
IHE Integrating the healthcare enterprise
NEN Nederlands normalisatie-instituut
NTA Nederlandse Technische Afspraak
PM Pacemaker
SMS Short message service
VVIR Mode of ventricular cardiac pacing
VT Ventricular tachycardia
Chapter 1: introduction
Cardiovascular implantable electronic devices (CIED) are
categorised as implantable pacemakers (PM), implantable
cardioverter-defibrillators (ICD), cardiac resynchronisation
therapy devices with or without a cardiac defibrillator and
cardiac arrhythmia monitor devices. After CIED implantation
regular technical checks of the CIEDS are mandatory to
examine the performance, safety and remaining longevity of
the implanted device. In addition, an in-hospital examination
of the device recipient (device patient) is sometimes needed to
evaluate his/her physical and mental condition and if required,
to adjust the function of the CIED to the changing needs of the
device recipient. Guidelines recommend the frequency and
intensity of these medical and technical follow-up visits. [1, 2]
Recently remote CIED interrogation from a patient’s resi-
dence has been introduced as a novel method of care in
cardiology [3–18]. With transtelephonic methods, technical
information is collected about the attributes, settings and
status of CIED and where applicable delivery of electrical
therapy by CIED and the resulting outcome. Some physiolog-
ical parameters of the device patient can also be monitored.
This remote interrogation can be used for scheduled and
unscheduled technical and patient monitoring and follow-up.
This information can result in alerts that may require a
response from the cardiologist or allied professional.
How remote monitoring contributes to patient care has been
reported in several recent studies. [9, 15, 17, 18] However the
indications, clinical relevance, cost effectiveness, management
and organisation of remote monitoring are hardly established
by prospective randomised trials. [16, 19–21] In addition many
organisational and legal aspects as well as reimbursement are
still a matter of dispute. Consequently remote monitoring of
CIED is now carried out in a very variable and fragmentedway
in daily practice and lacks a uniform methodology, thus creat-
ing uncertainty for all the parties involved. [22]
To overcome this uncertainty it is crucial to make an
inventory of all the components of remote monitoring in
order to promote a uniform methodology in clinical practice.
This consensus report intends to elucidate these components
and explores the pitfalls hampering a standard care of device
patients in terms of quality, technical and legal issues, safety,
costs and reimbursement. In the absence of a high level of
evidence (class 1), cardiology experts and those from vari-
ous disciplines contributed to the advisories and conclusions
of this consensus report. These efforts resulted in a prelim-
inary series of recommendations for remote monitoring.
This consensus report aims to become the founding base
for future guidelines for remote monitoring of CIED to
develop in the Netherlands. [23]
Footnote 1. Although the acronym AIMD (Active Im-
plantable Medical Device) is used in the Medical Device
Directive 93/42/EEC, in this document the term CIED
(Cardiovascular Implantable Electronic Device) is employed,
as this term limits the AIMDs to those used only for
cardiovascular application.
Footnote 2. Remote CIED monitoring potentially enables
reprogramming of operational device algorithms, e.g. to
adapt pacing features. Although this approach reflects true
‘remote cardiac rhythm management’ its application does
not appear advisable at this moment due to unknown safety
issues and legal uncertainties and needs to be investigated.
Chapter 2: technical description of remote monitoring
The communication chain
Remote monitoring is capable of sending information from a
CIED about programmable features, information on device
function, arrhythmias, cardiovascular haemodynamic infor-
mation, patient clinical status and registrations of stored elec-
trograms to an external device, the transmitter. This
transmitter has to be in the proximity of the patient to be able
to communicate with the CIED. When the transmitter has
received the data stream from the CIED, it sends these data
encrypted to a central server of the manufacturer of the CIED.
The manufacturer’s device provides these data in a pro-
tected environment for the cardiologist or allied professional;
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these data are suitable for incorporation in the hospital
information system (HIS). In contrast to in-hospital con-
tinuous cardiac rhythm monitoring, in remote monitoring
the CIED only communicates with the transmitter at
scheduled times, e.g. once a day.
In case of special events detected by the CIED or trig-
gered by the patient, the transmitter will send a non-
scheduled transmission to the server, which will be deliv-
ered to the cardiologist or allied professional by e-mail and/
or short message service (SMS). When no abnormalities are
detected, a transmission occurs as a scheduled agenda-based
virtual follow-up. Although the CIED continuously collects
data, the transmitter will only send the data according to
scheduled time intervals, e.g. once every day. Thus in a
technical sense, no continuous 24 h/day, 7 days/week mon-
itoring of the device and/or of the CIED patient has been
possible until now. Device companies cannot be held re-
sponsible for delays or lack of alerts and follow-up due to a
failing landline or global system for mobile communications
(GSM) technology.
Communication between CIED and transmitter (Fig. 1)
To remotely monitor a patient, the data from the CIED are
transferred to the hardware installed at the patient’s home. The
initial method to communicate with the CIED is the classic
induction coil, known as the programming wand. The coil has
to be placed within centimetres over the implanted device.
This communication depends on patient compliance. Today’s
CIEDs are equipped with bidirectional radio-frequent (RF)
communication, operating in the frequency range between
403 MHz and 406 MHz. With the use of this radio technique,
data are automatically sent from the CIED to a local transmit-
ter in the direct proximity of the patient.
Communication between the transmitter
and the manufacturer’s remote monitoring data centre
The data are forwarded to the manufacturer’s remote mon-
itoring data centre. A transmitter is used to receive, amplify
and transmit the signals. The data can be sent to the manu-
facturer’s remote monitoring data centre by the conventional
telephone cable network often called a ‘landline’ or by a
digital cellular phone technology such as general packet
radio service (GPRS) or satellite. All communication
between the transmitter and the manufacturer’s data
centre should be encrypted to guarantee patient privacy
and safety [24].
Communication between the manufacturer’s data centre
and the cardiologist
The raw data are received in the manufacturer’s remote
monitoring data centre where the data are automatically
transformed to a format that is readable for the cardiologist
and allied professional using the internet.
Footnote 3: In this report this device is designated as a
transmitter rather than the more appropriate but unfamiliar,
generic term transponder
The manufacturer’s graphical user interface (GUI) per-
mits scrolling through the stored data to allow analysis by
the cardiologist or allied professional. The presented data
have an identical format to the programmer-based interro-
gation during an in-hospital visit. In addition the manufac-
turer’s system analyses and compares the data with
programmed values to produce alerts. Alarm messages are
sent by e-mail or by digital cellular phone short message
service (SMS).
Interoperability
To promote an integral follow-up of the device patient, all
information including remote monitoring data should be
instantaneously and centrally available to the cardiologist
or allied professional. Interoperability in remote CIED mon-
itoring is therefore imperative. To ensure this approach, the
technology and contents of the information must be
exchangeable by applying standards on various levels
of processing, communication and semantics.
The ultimate target is the avoidance of any handwritten
file but direct automated reading and filling out of data from
the patient at home to the electronic patient document (EPD)
of HIS saving time and preventing flaws.
Fig. 1 Global overview of remote monitoring and remote follow-up
data flow
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Communication between the manufacturer’s data centre
and the hospital information systems
Patient data should be regarded as part of the patient
file and should be stored in the HIS. Nowadays differ-
ences exist between the format and screen displays of
the device manufacturers and the local HIS. This dif-
ference inhibits a uniform approach to storing and dis-
playing remote monitoring data. Efforts should be made
to implement, on a nationwide scale, the Integrating the
Healthcare Enterprise (IHE) specification of Implantable
Device–Cardiac–Observation (IDCO) for data from the
CIED. This specification together with the IEEE
11073–10103–MDC-IDC Nomenclature constitutes the
foundation for exchange.
Communication between the manufacturer’s data centre
and the national health information technology
infrastructure
The concept of the national health IT infrastructure aims to
connect all well-maintained health information systems to
this infrastructure. The main component is the switch point
where an index of the location of record fragments of the
patient is maintained. Any accredited health care profession-
al is able to query the switch point for certain types of
information. The system will retrieve the requested infor-
mation from the sources that are linked to the switch board.
This infrastructure could potentially also be used to make
CIED data available for authorised cardiologists and allied
professionals and hospitals. The National Cardiac Devices
Registry (NCDR), founded by the Netherlands Society of
Cardiology, can contribute to this objective.
Chapter 3: indications, benefits and limitations
of remote CIED monitoring
Types of remote monitoring
Scheduled transmission of programmed alerts of either
device-related (e.g. abnormal lead resistance) or patient-
related (e.g. onset of atrial fibrillation) events from the
manufacturer’s remote monitoring system to the cardiologist
is most frequently applied at the moment. This type of
remote monitoring includes detection and mailing of events
that had initially been programmed by the cardiologist or
allied professional. The second type is transmission of a
patient-activated alert that indicates the occurrence of spe-
cific symptoms. The third type is “remote follow-up” de-
fined as remote device interrogation at scheduled intervals.
This method can partly replace the in-hospital technical
CIED control.
Indications for remote monitoring of implanted devices
Literature shows a wide spectrum of reasons to perform
remote CIED monitoring. [7, 8, 10–15, 17, 18, 25, 26]
The reason for CIED implantation, the severity of illness
of the device patient, and the opportunity to follow high-risk
CIED or field actions/safety alerts of devices appear bene-
ficial indications. [27] For devices and/or leads with a high
risk of technical malfunction or great technical complexity
(e.g. ICD) remote monitoring appears favourable. [28] Re-
mote monitoring can also be applied to document the un-
derlying cause of symptoms of the device patient
comparable with Holter monitoring. Because of the lack of
evidence on efficiency or cost-effectiveness, the indications
for remote CIED monitoring are currently hardly established
and therefore routine remote monitoring of patients with
PM, CRT or ICD should be evaluated in further studies.
[2, 4, 6, 16] If remote monitoring is applied, the cardiolo-
gist’s decision is based on assumed better patient care and/or
quality of life and tailored to the individual patient.
Timing of response to alerts
As stated in the technical description (see chapter 2) routine
remote CIED monitoring cannot offer a continuous surveil-
lance of the device patient. Consequently a 24 h/day, 7 days/
week alert response from the cardiologists to the device
patient is not technically feasible. Furthermore evidence of
cost-effectiveness of continuous remote monitoring in terms
of an immediate response of the cardiologist or allied pro-
fessional to the alerts is hardly documented [3, 6, 16, 21].
In-hospital visits additional to remote CIED monitoring
Current guidelines for CIED follow-up advise on methods
and frequency of technical controls. For conventional
follow-up at least one visit per year for the simplest single-
chamber PM and 6 monthly follow-up for the more complex
dual-chamber PM is advised whereas for the ICD patient
after the 1st implantation or replacement a more frequent
follow-up is recommended. [1] In congestive heart failure
and CRT the course of the failing heart or incidence of
arrhythmia determine the intervals of in-hospital visits [1].
Regarding remote CIED monitoring it is recommended that
any patient with a CIED is assessed in person at least once a
year. [2] However the frequency of the in-hospital visits has
to be left to the cardiologist’s discretion.
Benefits of remote CIED monitoring
The major advantage of remote CIED monitoring is the
timely detection of CIED failures or deviations of the
programmed device values. A fast response to mailed alerts
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by the cardiologist or allied professional can prevent poten-
tial harm to the device patient. [8, 10, 12, 13, 15, 17, 18, 25]
Secondly, scheduled remote CIED follow-up can save the
time and efforts of the cardiologist and allied professional
and of the device patient and the accompanying family by
avoiding in-hospital visits for technical CIED follow-up.
Thirdly, remote CIED monitoring can be used for temporary
purposes such as rapid detection of technical failures related
to field action/safety alert or avoidance of frequent controls
at the time of anticipated battery depletion of the implanted
device. Fourthly, it is expected that remote monitoring can
counteract the pending imbalance between the annually
increasing load of care in more, older and more complex
CIED patients [29–31].
Limitations of remote monitoring
Remote CIED monitoring delivers a substantial amount of
data to be handled by the cardiologist and allied profession-
al. This overflow is intrinsically related to continuous mon-
itoring and storage of CIED measurements as well as to
stored cardiac and biological signals of the device patient
that are transmitted to the manufacturer’s remote monitoring
centre at scheduled intervals. Their clinical relevance is
often unknown in terms of risk and prognosis. This infor-
mation may falsely initiate the prescription of drugs or force
unnecessary CIED reprogramming and hospital referral
leading to over-treatment.
Apart from the clinical consequences, the overflow of
data generated by remote monitoring may increase the daily
workload of the cardiology staff thus requiring more per-
sonnel and budget. Remote monitoring might unfavourably
affect the attitude of the device patient because this ap-
proach can be falsely appreciated as an alternative route to
unrestricted and immediate access to care. Furthermore,
alerts and other information resulting from remote monitor-
ing may disturb the mental condition and health perception
of the device recipient. [32–34] These potential disadvan-
tages require further specific studies. Anticipating the results
of these studies, one should accept that alerts and responses
to alerts are reserved for specific conditions such as techni-
cal failures or abnormalities of CIED function specified in
the monitoring protocol of the individual device recipient
Measurements of quality of care of remote monitoring
Because of the novelty of this type of patient care, which
elicits uncertainty about benefit, adverse effects and costs,
measures to determine the quality of care are urgently need-
ed. Clinical and technical characteristics that predict poten-
tial benefit of remote monitoring have to be developed. The
set of recommendations delivered in this document by
experts can serve as a standard (see chapter 7). Current
technology of transmission, storage, alerts and communica-
tion between the manufacturer’s remote monitoring centre,
cardiologist and allied professional and HIS will further
develop and these products should also be incorporated in
the predictors of benefit.
Conclusions
1. Remote CIED monitoring can be applied but its indica-
tions are hardly scientifically established. Therefore re-
mote monitoring cannot be considered obligatory
patient care and is left at the cardiologist’s discretion
in daily practice.
2. From the technical point of view remote CIED moni-
toring does not imply continuous monitoring but sched-
uled or unscheduled information to the cardiologist or
allied professional. Until now evidence is lacking to
justify 24 h/day, /7 days/week based remote monitoring.
Waiting for clear evidence, handling of remote monitor-
ing should be restricted to hospital office hours.
3. Considering the benefits and limitations of remote mon-
itoring, prospective comparative studies are needed to
assess the contribution of remote CIED monitoring to
the care of the device patient. The cost-effectiveness of
the indications for various CIED categories and predic-
tors of benefit should be assessed.
4. Technical developments of remote monitoring require
interaction with manufacturers to facilitate uniform
methods of care and guarantee clinical relevance of
remote monitoring.
Chapter 4: the role of the patient in remote monitoring
Patient participation
Remote CIED monitoring relies on regular contact between
the device recipient and transmitter at scheduled intervals (e.g.
at home during the night). Therefore the device recipient must
be in the proximity of the transmitter. Patient compliance
includes matching of mental functioning as well as the visual
and hearing capacities of the device patient to proper handling
of the communication system. Remote monitoring also relies
on patient accessibility for alerts from the hospital and
counselling by the cardiologist and allied professional.
Continuous surveillance
The device patient might perceive that remote CIED moni-
toring brings out a continuous surveillance of the implanted
device and cardiac rhythm. However, as stated in chapter 2,
transmitting of surveillance data occurs at regular intervals
and not continuously. The same holds for delivery of alerts
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to the hospital. A delay in receiving a transmission can
occur which rules out continuous monitoring.
The internet communication can be falsely perceived as
an alternative route to immediate or easy access to patient
care in the hospital or emergency department. However,
alerts and response to alerts have to be reserved for specific
conditions, technical failures and particular appointments
with the patient. A commitment of the patient to the appro-
priate use of remote CIED monitoring is therefore indis-
pensable (see 7b Patient management).
Responsibilities
Patients receiving remote CIED monitoring should accept
responsibilities for proper handling and care of the transmit-
ter, prevention of damage and measures for proper commu-
nication with the device centre. These aspects are already
formalised by current legal rules of ownership, in terms of
“good clinical practice”. [35] Information to the device
patient should point to these responsibilities regarding all
parts of remote monitoring and follow-up. In case of serious
acute events the patient should ask for care in the conven-
tional way.
Ownership of the transmission system
Until now, the payment for the transmitter and additional
tools has varied widely and markedly. The total cost has
until now been compensated by the health insurance com-
pany. Hospital variations occur in the payment of transmitter
hardware. Sometimes the cost of the transmitter is included
in the device costs but in other circumstances the transmitter
is charged separately. Therefore a uniform format for reim-
bursement of all facilities for remote monitoring, namely
incorporation in the reimbursement structure, is strongly
advocated.
Transmitters are paired to a unique CIED and therefore
they are not exchangeable between patients. This inhibits
the transfer or loaning of the transmitter to other device
patients, e.g. after death. Technical facilities for exchange
of the transmission systems can promote flexibility of re-
mote monitoring. If patient ownership were to be aban-
doned, the hospital could become the owner of the
transmission systems. It is, however, unclear whether this
transition would reduce investments and maintenance time.
Conclusions
1. The implementation of remote CIED monitoring in
hospitals also involves patient information about
the expectations and restrictions of this method,
and the contribution and responsibilities of the device
patient.
2. The ownership of the transmitting systems by the hos-
pital can promote the flexibility of remote monitoring
for reuse but it is unclear whether this approach will
reduce the overall costs.
3. Organisations of CIED patients should be asked to
participate in the provision of patient information about
these subjects in order to facilitate a good perception of
the advantages and disadvantages of remote CIED
monitoring.
4. It is advised to compose a written consent between the
hospital or cardiologist and the patient regarding the re-
spective responsibilities, duties and limits of remote CIED
monitoring. Several subjects should be addressed such as
the responsibility for the analysis of the transmitted data,
timing of analysis of transmitted data and feedback to the
patient, and regulations about unscheduled transmissions.
Chapter 5: the contribution of the device manufacturer
to remote monitoring
Introduction
The development of remote CIED monitoring was started
many years ago initially to employ technical follow-up by
telephone. [25, 26, 36, 37] For the device manufacturer
remote monitoring also constituted a tool to follow devices
that were assigned as field action/safety alert or high risk for
sudden failure. Furthermore data of remote monitoring can
be used after informed patient consent for assessment of
long-term CIED performance contributing to improved
post-market CIED surveillance.
The market competition of the device branch has resulted
in a large variety of tools due to differences in design,
presentation of collected data, programming facilities and
communication features. Such a variety may have a negative
impact on patient safety as clinicians may get confused
when they deal with different manufacturers that handle
critical issues in different ways. In the past the responsibil-
ities of the CIED manufacturers with regard to security and
confidentiality resulted in a series of USA and European
regulations. However, implementation of remote CIED
monitoring clearly enlarges the manufacturer’s responsibil-
ities and these should be clarified. These aspects and the
manufacturer’s interaction with the cardiologist, allied pro-
fessional and hospital also need to be formalised.
Privacy
Transmitted data and alerts may be communicated by the
device provider through e-mail or by telephone or SMS and
received in the hospital. These messages must be encrypted
to guarantee patient privacy. Access to manufacturers’
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websites to assess CIED data of specific patients should also
take place in a secure way (https).
Safety
The accuracy of data receipt in the manufacturer’s remote
monitoring centre, data transmission to the hospital and
priorities with respect to alerts are the manufacturer’s re-
sponsibility. The manufacturer is responsible for the 24 h/
day, 7 days/week availability of service but can make agree-
ments about a temporary gap in monitoring for specific
reasons.
However the manufacturer cannot be held responsible for
failures due to insufficient patient instruction delivered by
the cardiologist or allied professional or the misinterpreta-
tion of those instructions by the patient. This also applies for
failed transmission, temporary delay or missing alerts due to
disorders of landline or GSM technology; in principle tele-
com service providers are responsible for this part of the
communication link, though the manufacturer has the re-
sponsibility to select a reliable provider.
Because remote monitoring is susceptible to computer
security breaches of various origins, performance, safety
and privacy are at stake, requiring specific security controls.
A minimum format for secure data transport is mandatory
for both manufacturer and hospital environment. [25]
Storage of technical and patient data
The manufacturer is not the owner of the patient data.
Patient data should be regarded as part of the patient file
and therefore should be stored for a limited time in the
manufacturer’s remote monitoring system; appropriate
back-up of all data is needed. Patient data should be treated
according standard rules (NEN 7510).
Storage of patient data ends after final transmission of
data to the hospital where storage is obliged over a 15-year
interval. [38] If the manufacturer wants to analyse or store
patient data longer, non-reversible transformation into an
unidentifiable format is necessary.
Technical developments
The current technology of remote monitoring will further
develop by data reduction, communication with electronic
patient records and personal health records and by adding
more features. These developments require interaction be-
tween CIED manufacturers and health care providers to
promote uniform methodology and to evaluate the clinical
relevance of technical progress. To avoid clinically irrele-
vant applications of remote CIED monitoring, interaction
between cardiology professionals and CIED manufacturers
should be intensified.
Conclusions
1. Regarding CIED remote monitoring, the responsibilities
of the device manufacturer and the local cardiology
professionals and hospital, respectively, should be for-
malised in a written agreement. This document covers
the technical, safety and privacy matters addressed in
this chapter as well as agreements about data storage
and mutual rights and agreements.
2. Uniformity in the methods of remote CIED monitoring
as well as standardised presentation of data ranks very
highly in the regulations to be developed between de-
vice manufacturers and cardiology professionals.
3. Today’s regulations for safety and privacy of CIED
applicable to CIED manufactures have to be revisited
with the employment of remote CIED monitoring, par-
ticularly to prevent computer breaches of the device.
Chapter 6: costs and reimbursement of remote
monitoring
Cost components for the hospital
As shown in Fig. 1 (see chapter 2), the transmitter at the
patient’s residency, the manufacturer’s information technol-
ogy, terminals in the hospital and the HIS constitute linking
parts. The total cost of setting up the system, providing care
and maintaining the system can be divided into different
aspects:
Initial investments:
– Time and budget to connect the incoming data and
alerts to the HIS and to maintain these connections
and the database,
– The hospital and its cardiology department have to
reserve technical and human facilities for remote mon-
itoring and storage of the data,
– Organisational efforts,
– During the initial starting phase, the care providers have
to familiarise themselves with the system and need to
support the conventional follow-up.
Resource use:
– Reading and interpretation of the alerts or scheduled
remote follow-up,
– Patient instruction, telephonic and local checks of the
chain of transmission often at the patient’s residency,
– Response to and reassurance and counselling of the
patient at his residency by information about the
results,
– Administrative assistance for patient filing and storage
of data.
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Capital equipment:
– The transmitter at the patient’s residence.
Maintenance:
– Maintenance of the web-application/provider,
– Maintenance of the database,
– Maintenance of the physical system at the patient’s
residence.
To date the purchase of the transmitter and associated
technical facilities as well as transmission of data and alerts
are usually free of charge for the patient.
Reimbursement of conventional CIED follow-up
Follow-up after CIED implantation and replacement carried
out according to current guidelines [1, 2] reimbursed by
insurance companies applying standard reimbursement rules
for this care. The follow-up includes at least one in-hospital
medical consultation and a technical check of CIED of
which the details are published at the website of DBC
Onderhoud (www.dbconderhoud.nl).
Reimbursement of remote CIED monitoring
Until now remote CIED monitoring has not been reim-
bursed by health insurance companies. [9, 29, 30] In the
absence of Dutch advisories or guidelines for remote CIED
monitoring, health insurance companies can refuse reim-
bursement to the cardiologist, hospital and manufacturer
and can ask for supplementary payment by the device pa-
tient. On the other hand with the purpose to improve quality
of care, insurance companies and health authorities can
propose the application of remote monitoring as the stan-
dard method. From the patient perspective, remote monitor-
ing appears very attractive. The initial reports point to a
significantly better health perception of the device patient
with remote monitoring because of the perceived “short
distance care” and easy access to the hospital. [11, 13, 16,
30] This additional gain of health perception therefore jus-
tifies additional costs. Furthermore, if remote monitoring
becomes an evidence-based type of care for the CIED pa-
tient, payment by the device patient for remote monitoring is
inappropriate and should be covered by the health insurance
company.
The costs for the cardiologists and hospital are complete-
ly unknown at the moment because implementation of re-
mote CIED monitoring runs parallel with standard
outpatient follow-up and requires extra investments in in-
formation technology, more highly qualified personnel and
other measures in the initial years. In view of all these
matters it is unclear whether the financial balance will end
positively; this lack of knowledge requires prospective cost-
effectiveness studies in the Dutch healthcare setting [19]
It appears logical to incorporate remote CIED monitoring
in the existing generic DBC structure. Pilot studies can
already be started to examine the impact on time and costs
of various technical and human components of remote
CIED monitoring as well as the reasons for and frequency
of remote monitoring.
Conclusions
1. Remote CIED monitoring is technically feasible and may
offer beneficial care in specific indications. However, it has
a major impact on time, technical facilities and personnel,
and therefore appropriate reimbursement is needed.
2. Reimbursement is preferable through the existing ge-
neric reimbursement structure.
3. Short-term pilot studies are requested to evaluate the
frequency of and reasons for remote CIED monitoring
currently done in the Netherlands to define the degree
and level of reimbursement without delay.
4. Cost-effectiveness studies of remote CIED monitoring
should be initiated to evaluate the efficiency of various
indications for remote monitoring in the Dutch health
setting. The results should be used for fine-tuning of the
current reimbursement structure.
5. Remote CIED monitoring can become a standard com-
ponent of CIED patient care with indications based on
evidence and guidelines.
Chapter 7: preliminary recommendations for remote
CIED monitoring
a. Technical features
1. Contents of alerts
Initial experience with remote CIED monitoring
delivered a series of preliminary recommendations
for the content of default or optional programmed
alerts. Table 1 recommended minimal device settings
in remote monitoring.
2. Application of scheduled remote CIED monitoring
For all CIEDS default and optional alert features
can be installed.
PM: Optional alert features include the detection
of atrial and ventricular arrhythmia events, percen-
tages of atrial and/or ventricular pacing, rate histo-
grams and sensor driven pacing rhythms; this
information can contribute to optimal individualised
pacing.
ICD: The detection of VF, VT and all VT types
resulting in ICD discharge, aborted shocks and the
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number of appropriate and inappropriate shocks is
indispensable to get insight into ICD functioning.
Monitoring of the intrinsic ventricular signal for
sensing has a high priority.
CRT: The percentage of biventricular ventricular
pacing is a paramount feature of CRT functioning.
3. Triggered event monitoring: For all CIEDs specific
default and optional alert features can be installed as
advised for scheduled monitoring.
4. Comments on contents of remote monitoring:
4a. Programming of the alert feature for the event
VT requires a definition of this arrhythmia.
According to the expert view VT is defined as
a rate >180/m for 30 s because this pattern is
associated with symptoms and risk.
4b. Programming of the alert feature for the impact
of AF requires a definition of this arrhythmia.
According to expert view, mode switch of the
pacing device after AF detection to VDIR or
DDIR >10% of day time and >2 days monthly
is classified as a serious AF incidence. Since
inappropriate mode switch has been reported
additional conformation is required. [39]
4c. It is advocated not only to rely on actual data
of the alarm but also to get insight into
trends of the concerning alarms, e.g. course
of lead resistance.
4d. Not only the actual value of a measurement, e.g.
abnormal battery impedance, but also facilities
for comparing previous data permitting a trend
evaluation are strongly recommended.
Table 1 Recommended minimal device settings in remote monitoring
Condition Device Default Optional Scheduled Unscheduled
Battery PM/ICD/CRT Battery Impedance X
PM/ICD/CRT Estimated Replacement time (ERT) X X
ICD Capacitor charge time X
ICD Capacitor charge time > 18 seconds X X
Leads Lead Impedance X
PM/CRT/ICD 20% Deviation of normal values X X
ICD Shock impedance X
ICD Shock impedance out of range X X
Sensing PM/ICD/CRT Intrinsic atrial signals X
PM/ICD/CRT Intrinsic ventricular signals X
PM/ICD/CRT 20% Deviation of normal values Detection of interference X X
Threshold PM/ICD/CRT Automatic atrial capture management X
PM/ICD/CRT Automatic ventricular capture management X
PM/ICD/CRT 20% Deviation of normal values X X
Programming ICD VT/VF therapy disabled X
PM/ICD/CRT Device reset X X
Arrhythmias PM/ICD/CRT Incidence X
PM/ICD/CRT Duration X
PM/ICD/CRT Supraventricular events X
PM/ICD/CRT Duration of AF exceeds consented time X X
PM/ICD/CRT Ventricular events X X
ICD VT Therapy X X
ICD VF therapy X X
ICD More than 3 therapies needed for termination X X
ICD Therapy not successful X X
Heart rate PM/ICD/CRT % Atrial and ventricular pacing X
% Atrial and ventricular sensing X
Rate histograms (intrinsic) X
Sensor driven rate histograms X
Heart failure PM/CRT/ICD Heart failure monitoring parameters X X
CRT % biventricular pacing X X
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7b. Patient management
Because written information is a crucial factor for a
safe and accurate remote CIED monitoring and follow-
up, it is advised to formulate an outline with minimal
requirements of information for nation-wide use. The
following elements should be addressed:
1. The device patient should be informed in such a
way that he/she is aware that regular follow-up by
remote monitoring is a safe and convenient way to
replace some in-hospital visits. Remote CIED mon-
itoring is not a continuous process but has to be
limited to the “office-hours” of the hospital. The
information should include that alerts will be
responded to within a reasonable timeframe (e.g.
in the day of receipt). The patient and provider
should be familiar with this timing to avoid any
misunderstanding.
2. The timing of response to an alert (patient and
physician response time respectively) should be
agreed between the patient and the cardiologist
and allied professional. Regulations should be
agreed on how to reach the patient and the timing
necessary to warn the device patient after a received
alert. The impact of alerts resulting in any action
(sometimes hospital referral) should be addressed.
Since the stored data are part of the medical file, the
patient should be permitted to inspect his/her own
data.
3. Patients with remote CIED monitoring need to be
informed about the results of the technical follow-
up of the device and/or consequences of alerts. The
frequency, intensity and timing of this information
should be agreed between the cardiologist and allied
professional and the device patient.
4. Consequences of the ownership of the equipment
for remote CIED monitoring need to be clarified.
The proper handling, consequences of damage and
misuse of the transmission equipment need to be
addressed.
5. The patient should be informed about the outcome
of remote monitoring of his/her device. Further-
more, measures to prevent abuse of remote moni-
toring or unnecessary referral to the hospital can be
given.
6. The patient should inform the cardiologist or allied
professional in case of an absence of more than
20 days or any differently agreed interval to main-
tain the communication between provider and car-
diologist and allied professional.
7. Electrical discharges, whether appropriate or not,
will trigger alerts or evoke patient activated alerts.
The ICD patient should be aware that these alerts
can have major consequences, e.g. the temporary
withdrawal of the driving license.
8. The responsibility and contribution of the device
manufacturer and internet provider for the execution
of remote CIED monitoring should be clarified.
9. The information about remote monitoring of
implanted devices is to be presented in easily un-
derstandable text and the cardiologist or allied pro-
fessional and device patient have to sign that the
information has been given orally and that written
information has been received. The oral information
can be given per patient or in groups of device
patients.
7c. The in-hospital protocol of remote CIED monitoring:
It is advised to compose an in-hospital protocol for
remote CIED monitoring to describe the tasks and
responsibilities of the cardiologist, allied professional
and hospital management. [40] This protocol contains
the indications for remote monitoring, programming of
alerts and technical, organisational and administrative
components of remote monitoring. It is advised to
formulate an outline with minimal requirements for
nationwide use, containing the following elements:
1. To perform remote monitoring specific cardiac
knowledge, skills and experience of cardiac
arrhythmias and CIEDs are necessary for the cardi-
ologist and allied professional. Hospitals with a
licence to perform ICD implantations and hospitals
without this licence but with an agreement with a
licensed hospital can perform remote ICD monitor-
ing and follow-up, provided clear written rules on
responsibilities are specified. Hospitals without a
licence to perform ICD implantations have to meet
the same rules and regulations concerning ICD
follow-up according to the Dutch Guidelines for
ICD implanting centres. [41] All hospitals are free
to execute remote monitoring of PM and CRT.
2. The cardiologist decides on the indication, the
programming of alerts, frequency and duration of
remote CIED monitoring. The cardiologist can
transfer these activities to allied professionals
according to the standing in-hospital protocol. Mu-
tual interaction between cardiologist and allied pro-
fessional is necessary to promote safety and
relevance of programming and of responses to
alerts.
3. The protocol also addresses the written information
to the patient, and the priorities and logistic routes to
cope with alerts and responses to alerts. The proto-
col should also underscore that alerts and other
remote monitoring data will be responded to within
a reasonable time.
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4. To avoid loss of patient information the communi-
cation between the remote monitoring chain and the
hospital EPD should be encouraged. The cardiology
department and the board of the hospital should
supervise the contents, quality and implementation
of this in-hospital protocol and the written informa-
tion to the patient.
5. The protocol requests regular upgrading and can
serve as a measure to assess the quality of care of
device patients in the hospital.
Addendum
Technical standards for remote CIED monitoring
1. Technical standards
The Netherlands Standardization Institute (NEN) has
drafted a Nederlandse Technische Afspraak (NTA) which,
besides defining Telemedicine, covers the quality aspects of
Telemedicine. This NTA is now being revised and will
become a Dutch national standard. It will contain require-
ments for telemedicine providers to develop a quality sys-
tem that will monitor the risks associated with the service.
As soon as this standard becomes available it is advisable to
apply this standard for the remote monitoring and remote
follow-up of CIEDs.
2. Quality of the data communication
Transmitted data are labelled to the unique serial number
of the implanted device to prevent patient data being mixed
between patients. Data integrity and communication be-
tween device, transmitter and the manufacturer’s remote
monitoring data centre, are the responsibility of the manu-
facturer. Data encryption is thought to be energy consuming.
Encryption is done by the transmitter. The frequent interro-
gation of the device is battery consuming (estimated
3 months of a lifetime).
Regarding the access of data stored at the manufacturer’s
remote monitoring data centre, mails and SMS messages
should all comply with the Code of Practice for Information
Security Management.
3. Currents standards for connectivity can be assigned in
three levels
The functional specifications of interconnectivity can be
found in documents published by Integrating the Health-
care Enterprise (IHE). IHE is an initiative by healthcare
professionals and industry to improve the way computer
systems in healthcare share information. IHE promotes the
coordinated use of established standards such as DICOM
and HL7 to address specific clinical needs in support of
optimal patient care. Furthermore IHE defines and publishes
technical frameworks for developers and users.
By defining the syntax of message formats and commu-
nication rules DICOM and HL7 defines technical specifica-
tions. HL7, which is an abbreviation of Health Level Seven,
is a standard for exchanging information between medical
applications. This standard defines a format for the trans-
mission of health-related information. “Level Seven” refers
to the seventh level of the International Organization for
Standardization (ISO) seven-layer communications model
for Open Systems Interconnection (OSI)–the application
level. Digital Imaging and Communications in Medicine
(DICOM) is a standard for handling, storing, printing, and
transmitting information in medical imaging.
For interoperability it is important that, after sending an
observation taken by the implanted device, the semantics of
the observation are clearly defined. IEEE 11073–10103
characterises clinical terms by defining correct descriptions
and definitions. It provides the nomenclature for the clinical
observations taken by CIEDs.
Technical References
1.NEN 7504:2004 Medische Met vriendelijke groet, in-
formatica–Berichtenverkeer–Zorginformatiesystemen–Toe-
passing van de HL7-berichtenstructuur in zorginstellingen
in Nederland–Eisen en toelichting van HL7-versie 2.4; 2.
Nen 7510, 2004. Informatiebeveiliging in de zorg. May
2005 at http://www.nen7510.org 3. ISO/HL7 27931:2009.
DataExchange Standards—Health Level Seven Version 2.5
—An application protocol for electronic data exchange in
healthcare environments 4.. ISO/TS 13606:2009. Elec-
tronic health record communication
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution Noncommercial License which permits any
noncommercial use, distribution, and reproduction in any medium,
provided the original author(s) and source are credited.
References
1. Vardas PE, Auricchio A, Blanc JJ, et al. Guidelines for cardiac
pacing and cardiac resynchronization therapy: the Task Force for
Cardiac Pacing and Cardiac Resynchronization Therapy of the
European Society of Cardiology. Developed in collaboration with
the European Heart Rhythm Association. Eur Heart J. 2007;28
(18):2256–95.
2. Wilkoff BL, Auricchio A, Brugada J, et al. HRS/EHRA expert
consensus on the monitoring of cardiovascular implantable elec-
tronic devices (CIEDs): description of techniques, indications,
personnel, frequency and ethical considerations. Hear Rhythm.
2008;5(6):907–25.
3. Al Khatib SM, Piccini JP, Knight D, et al. Remote monitoring of
implantable cardioverter defibrillators versus quarterly device
interrogations in clinic: results from a randomized pilot clinical
trial. J Cardiovasc Electrophysiol. 2010;21(5):545–50.
Neth Heart J (2012) 20:53–65 63
4. Fauchier L, Sadoul N, Kouakam C, et al. Potential cost savings by
telemedicine-assisted long-term care of implantable cardioverter
defibrillator recipients. Pacing Clin Electrophysiol. 2005;28 Suppl
1:S255–9.
5. Halimi F, Clementy J, Attuel P, et al. Optimized post-operative
surveillance of permanent pacemakers by home monitoring: the
OEDIPE trial. Europace. 2008;10(12):1392–9.
6. Heidbuchel H, Lioen P, Foulon S, et al. Potential role of remote
monitoring for scheduled and unscheduled evaluations of patients
with an implantable defibrillator. Europace. 2008;10(3):351–7.
7. Lazarus A. Remote, wireless, ambulatory monitoring of implant-
able pacemakers, cardioverter defibrillators, and cardiac resynch-
ronization therapy systems: analysis of a worldwide database.
Pacing Clin Electrophysiol. 2007;30 Suppl 1:S2–S12.
8. Lunati M, Gasparini M, Santini M, et al. Follow-up of CRT-ICD:
implications for the use of remote follow-up systems. Data from
the InSync ICD Italian Registry. Pacing Clin Electrophysiol.
2008;31(1):38–46.
9. Morichelli L, Ricci RP. Remote monitoring of implantable devices:
the European experience. Hear Rhythm. 2009;6(7):1077–80.
10. Nielsen JC, Kottkamp H, Zabel M, et al. Automatic home moni-
toring of implantable cardioverter defibrillators. Europace.
2008;10(6):729–35.
11. Raatikainen MJ, Uusimaa P, van Ginneken MM, et al. Remote
monitoring of implantable cardioverter defibrillator patients: a
safe, time-saving, and cost-effective means for follow-up. Euro-
pace. 2008;10(10):1145–51.
12. Ricci RP, Morichelli L, Santini M. Home monitoring remote
control of pacemaker and implantable cardioverter defibrillator
patients in clinical practice: impact on medical management and
health-care resource utilization. Europace. 2008;10(2):164–70.
13. Ricci RP, Morichelli L, Quarta L, et al. Long-term patient accep-
tance of and satisfaction with implanted device remote monitoring.
Europace. 2010;12(5):674–9.
14. Santini M, Ricci RP, Lunati M, et al. Remote monitoring of
patients with biventricular defibrillators through the CareLink
system improves clinical management of arrhythmias and heart
failure episodes. J Interv Card Electrophysiol. 2009;24(1):53–61.
15. Saxon LA, Hayes DL, Gilliam FR, et al. Long-term outcome after
ICD and CRT implantation and influence of remote device follow-
up: the ALTITUDE Survival Study. Circulation. 2010;122
(23):2359–67.
16. Schmidt S, Schuchert A, Krieg T, et al. Home telemonitoring in
patients with chronic heart failure: a chance to improve patient
care? Dtsch Arztebl Int. 2010;107(8):131–8.
17. Theuns DA, Rivero-Ayerza M, Knops P, et al. Analysis of
57,148 transmissions by remote monitoring of implantable
cardioverter defibrillators. Pacing Clin Electrophysiol.
2009;32 Suppl 1:S63–5.
18. Varma N, Michalski J, Epstein AE, et al. Automatic remote mon-
itoring of implantable cardioverter-defibrillator lead and generator
performance: the Lumos-T Safely RedUceS RouTine Office De-
vice Follow-Up (TRUST) trial. Circ Arrhythm Electrophysiol.
2010;3(5):428–36.
19. Goff-Pronost M, Sicotte C. The added value of thorough economic
evaluation of telemedicine networks. Eur J Health Econ. 2010;11
(1):45–55.
20. Hailey D, Ohinmaa A, Roine R. Study quality and evidence of
benefit in recent assessments of telemedicine. J Telemed Telecare.
2004;10(6):318–24.
21. Joglar JA. Remote monitoring of cardiovascular implantable elec-
tronic devices: new questions raised. Pacing Clin Electrophysiol.
2009;32(12):1489–91.
22. Halimi F, Cantu F. Remote monitoring for active cardiovascular
implantable electronic devices: a European survey. Europace.
2010;12:1778–80.
23. van Hemel NM. Remote monitoring of implanted cardiac devices:
a plea for a nationwide exploration. Neth Heart J. 2009;17
(11):434–7.
24. Maisel WH, Kohno T. Improving the security and privacy of
implantable medical devices. N Engl J Med. 2010;362(13):1164–
6.
25. Res JC, Theuns DA, Jordaens L. The role of remote monitoring in
the reduction of inappropriate implantable cardioverter defibrilla-
tor therapies. Clin Res Cardiol. 2006;95 Suppl 3:III17–21.
26. Schoenfeld MH, Compton SJ, Mead RH, et al. Remote monitoring
of implantable cardioverter defibrillators: a prospective analysis.
Pacing Clin Electrophysiol. 2004;27(6 Pt 1):757–63.
27. Maisel WH, Moynahan M, Zuckerman BD, et al. Pacemaker and
ICD generator malfunctions: analysis of Food and Drug Adminis-
tration annual reports. JAMA. 2006;295(16):1901–6.
28. Borleffs CJ, van Erven L, van Bommel RJ, et al. Risk of failure of
transvenous implantable cardioverter-defibrillator leads. Circ
Arrhythm Electrophysiol. 2009;2(4):411–6.
29. Merkely B, Roka A, Kutyifa V, et al. Tracing the European course
of cardiac resynchronization therapy from 2006 to 2008. Europace.
2010;12(5):692–701.
30. van Veldhuisen DJ, Maass AH, Priori SG, et al. Implementation of
device therapy (cardiac resynchronization therapy and implantable
cardioverter defibrillator) for patients with heart failure in Europe:
changes from 2004 to 2008. Eur J Heart Fail. 2009;11(12):1143–51.
31. Zayac S, Finch N. Recipients’ of implanted cardioverter-
defibrillators actual and perceived adaptation: a review of the
literature. J Am Acad Nurse Pract. 2009;21(10):549–56.
32. Kamphuis HC, de Leeuw JR, Derksen R, et al. Implantable car-
dioverter defibrillator recipients: quality of life in recipients with
and without ICD shock delivery: a prospective study. Europace.
2003;5(4):381–9.
33. Thomas SA, Friedmann E, Gottlieb SS, et al. Changes in psycho-
social distress in outpatients with heart failure with implantable
cardioverter defibrillators. Heart Lung. 2009;38(2):109–20.
34. van den Broek KC, Denollet J, Nyklicek I, et al. Psychological
reaction to potential malfunctioning of implantable defibrillators.
Pacing Clin Electrophysiol. 2006;29(9):953–6.
35. Gevers JK. Evaluation of the Dutch Medical Treatment Act
(WGBO). Ned Tijdschr Geneeskd. 2001;145(11):509–12.
36. Dreifus LS, Zinberg A, Hurzeler P, et al. Transtelephonic monitor-
ing of 25,919 implanted pacemakers. Pacing Clin Electrophysiol.
1986;9(3):371–8.
37. Platt S, Furman S, Gross JN, Andrews C, Benedek M. Trans-
telephone monitoring for pacemaker follow-up 1981–1994. Pacing
Clin Electrophysiol. 1996;19(12 Pt 1):2089–98.
38. Richtlijnen inzake het omgaan met medische gegevens vastgesteld
door de Algemene Vergadering van de KNMG op 15 december
2009. www.knmg.nl/dossier/medischegegevens 2010.
39. de Voogt WG, van Hemel NM. Clinical application of pacemakers
in atrial tachyarrhythmias. Neth Heart J. 208;16(Suppl 1):S20–
S24.
40. van Eck JW, van Hemel NM, de Voogt WG, et al. Routine follow-
up after pacemaker implantation: frequency, pacemaker program-
ming and professionals in charge. Europace. 2008;10(7):832–7.
41. NVVC praktijkrichtlijn voor ICD centra; implantaties en controles.
www.nvvc.nl. 2009.
List of participants
Organisational and writing committee: CC de Cock, MD PhD,
Department of Cardiology, VUmc, Amsterdam; J Elders, RN MA,
Department of Cardiology, Canisius Wilhelmina Hospital, Nijmegen;
NM van Hemel, MD PhD, Prof Em, Utrecht University.
64 Neth Heart J (2012) 20:53–65
Subject: technical aspects: J Talmon, PhD, Department of Medi-
cal Informatics, Maastricht University, chairman; MJ van der Ven,
Chairman of Project Team Telemedicine NEN; J Versluis, St Jude
Medical, Veenendaal; E.T van der Velde, PhD, Department of Cardi-
ology, UMC Leiden; PFHM van Dessel, MD PhD, Department of
Cardiology, AMC Amsterdam; P Boogaard, Cygnea, Mijdrecht.
Subject: contents of telemonitoring: DAMJ Theuns, PhD, De-
partment of Cardiology, Erasmus MC Rotterdam, chairman; PP Del-
noy, MD PhD, Department of Cardiology, Isala Klinieken Zwolle; P
van der Kemp, Sorin/Ela BV, Amsterdam; A Dijk, MSc, Thorax
Center, AMC Groningen; YS Tuininga, MD PhD, Department of
Cardiology, Deventer Hospital; JH Ruiter, MD PhD, Department of
Cardiology, Medical Center Alkmaar; ML Hendriks, MA, Department
of Cardiology, VUmc Amsterdam; R Jansen, Department of Cardiol-
ogy, Medical Center Alkmaar.
Subject: quality of care: L van Erven, MD PhD, Department of
Cardiology, LUMC, Leiden, chairman; W van den Broek, Med-
tronic Trading NL, Heerlen; B Springorum, Department of Cardi-
ology, Onze Lieve Vrouwe Gasthuis, Amsterdam; A van Kooten,
Department of Cardiology, Onze Lieve Vrouwe Gasthuis, Amster-
dam; ML Hendriks, MA, Department of Cardiology, VUmc
Amsterdam; G Paulussen, MD, Department of Cardiology, Atrium
Medical Center, Heerlen.
Subject: the role of users and providers:WG de Voogt, MD PhD,
Department of Cardiology, Sint Lucas Andreas Hospital, Amsterdam,
chairman; P Houdijk, Department of Cardiology, St Antonius Hospital,
Nieuwegein; HPG van Dorst, Biotronic Nederland BV, Nijmegen; Ch
Kirchhof, MD PhD, Department of Cardiology, Rijnland Hospital,
Leiderdorp; S Klaphake, Boston Scientific, Nieuwegein; P Stolwijk,
MD, Department of Cardiology, Rijnstate Hospital, Arnhem.
Subject: costs and payment: Ms G van Oort, MSc, St Jude
Medical, Veenendaal, chairman; M Siebert, St Jude Medical Bruxelles;
MLL van Genugten, Medtronic Trading NL, Heerlen; VPJM Seignette,
Senior Staff Officer, Financial and Management Department, Division
IV, VUmc, Amsterdam.
Subject: legal aspects and responsibilities: Prof B. de Mol, MD,
LLM, PhD, AMC Amsterdam, chairman; L. Bouwels, MD, Depart-
ment of Cardiology, Canisius Wilhelmina Hospital, Nijmegen; PMJ
Verhoeven, Department of Cardiology, St Antonius Hospital, Nieuwe-
gein; O. Swens, LLM, Vondst Advocaten, Amsterdam; W. van den
Broek, PhD, F. Böhmer, MBA; P. van Zeijst, Dutch Health Authority,
The Hague, G. van Laer, Medtronic, Belgium
Subject: the role of the patient:Kvan den Broek, PhD, Department
of Psychology, University of Tilburg, chairman, Rev. PH Zaadstra, rep-
resenting Dutch ICD Patient Organisation (STIN); R Derksen, MD,
Department of Cardiology, Rijnstate Hospital, Arnhem; AH Maass, MD
PhD, Department of Cardiology, UMC Groningen; C Hooijschuur, De-
partment of Cardiology, UMC Groningen; Mrs E Postelmans, RN,
Amphia Hospital, Breda; H Weetink, RN, Amphia Hospital, Breda; H
Versteeg, MSc, Department of Psychology, University of Tilburg; PMJ
Verhoeven, Department of Cardiology, St Antonius Hospital, Nieuwe-
gein; E. Prijs, Boston Scientific, Nieuwegein.
Neth Heart J (2012) 20:53–65 65
